This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

3 Health Care Stocks Under $10 to Watch

Geron

Geron (GERN) develops therapeutic products for cancer that inhibit telomerase. This stock is trading up 3.1% to $1.16 in recent trading.

Today's Range: $1.13-$1.16
52-Week Range: $0.91-$2.99
Volume: 275,000
Three-Month Average Volume: 767,800

>>5 Rocket Stocsk to Buy in June

From a technical perspective, GERN is bouncing higher here right off its 50-day moving average at $1.12 with lighter-than-average volume. This move is quickly pushing shares of GERN within range of triggering a major breakout trade. That trade will hit if GERN manages to take out some near-term overhead resistance levels at $1.20 to $1.22 and then once it clears more resistance at $1.25 with high volume.

Traders should now look for long-biased trades in GERN as long as it's trending above its 50-day at $1.12 or above some more key near-term support at $1.05, and then once it sustains a move or close above those breakout levels with volume that hits near or above 767,800 shares. If that breakout triggers soon, then GERN will set up re-test or possibly take out its next major overhead resistance levels at $1.40 to its 200-day moving average at $1.45. Any high-volume move above $1.45 to $1.51 will then put its next major overhead resistance levels at $1.78 to $1.83 into range for shares of GERN.

Rosetta Genomics

Rosetta Genomics (ROSG) develops diagnostic tests and therapeutic tools. This stock is trading up 10.2% to $4.02 in recent trading.

Today's Range: $3.73-$4.22
52-Week Range: $3.09-$17.35
Volume: 1.43 million
Three-Month Average Volume: 267,956

>>5 Hated Earnings Stocks That Deserve Your Love

Shares of ROSG are ripping higher today after the company announced plans to expand its U.S. commercial footprint from five sales territories currently to 12 territories beginning in July. The company also reported the successful launch of its new corporate and product branding at the recent American Society of Clinical Oncology Annual Meeting.

From a technical perspective, ROSG is soaring higher her right off its 50-day moving average at $3.74 with heavy upside volume. This move is quickly pushing shares of ROSG within range of triggering a near-term breakout trade. That trade will hit if ROSG manages to take out some near-term overhead resistance at $4.15 with high volume. At last check, ROSG has started to flirt with that breakout since the stock has hit an intraday high of $4.22 and volume is well above its three-month average action of 267,956 shares.

Stock quotes in this article: GERN, HEB, ROSG 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs